CRYSTAL

NCT00154102 📎

Regimen

Experimental
Cetuximab + FOLFIRI
Control
FOLFIRI alone

Population

Metastatic CRC, 1L; key efficacy in KRAS wild-type subgroup; foundational trial for the KRAS biomarker paradigm.

Key finding

1L mCRC (EGFR+, all-comer ITT): mPFS 8.9 vs 8.0 mo (HR 0.85, 95% CI 0.72-0.99, p=0.048); KRAS-wt subgroup: mPFS 9.9 vs 8.7 mo (HR 0.68, p=0.02); mOS 24.9 vs 21.0 mo (HR 0.796, p=0.0093); KRAS-mut: no benefit or trend toward harm

Source: PMID 19339720

Timeline

    Guideline citations

    • NCCN Colon (p.35)
    • NCCN Rectal (p.46)